↓ Skip to main content

Dove Medical Press

Article Metrics

Aflibercept in wet AMD: specific role and optimal use

Overview of attention for article published in Drug Design, Development and Therapy, August 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
1 tweeter
patent
4 patents

Citations

dimensions_citation
74 Dimensions

Readers on

mendeley
110 Mendeley
Title
Aflibercept in wet AMD: specific role and optimal use
Published in
Drug Design, Development and Therapy, August 2013
DOI 10.2147/dddt.s40215
Pubmed ID
Authors

Francesco Semeraro, Morescalchi, Sarah Duse, Francesco Parmeggiani, Gambicorti, Ciro Costagliola

Abstract

Vascular endothelial growth factor (VEGF) is a naturally occurring glycoprotein in the body that acts as a growth factor for endothelial cells. It regulates angiogenesis, enhances vascular permeability, and plays a major role in wet age-related macular degeneration. The consistent association between choroidal neovascularization and increased VEGF expression provides a strong reason for exploring the therapeutic potential of anti-VEGF agents in the treatment of this disorder. Blockade of VEGF activity is currently the most effective strategy for arresting choroidal angiogenesis and reducing vascular permeability, which is frequently the main cause of visual acuity deterioration. In recent years, a number of other molecules have been developed to increase the efficacy and to prolong the durability of the anti-VEGF effect. Aflibercept (EYLEA®; Regeneron Pharmaceutical Inc and Bayer), also named VEGF Trap-eye, is the most recent member of the anti-VEGF armamentarium that was approved by the US Food and Drug Administration in November 2011. Because of its high binding affinity and long duration of action, this drug is considered to be a promising clinically proven anti-VEGF agent for the treatment of wet maculopathy.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 <1%
Unknown 109 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 20%
Researcher 15 14%
Other 11 10%
Student > Bachelor 11 10%
Student > Master 10 9%
Other 25 23%
Unknown 16 15%
Readers by discipline Count As %
Medicine and Dentistry 37 34%
Agricultural and Biological Sciences 14 13%
Biochemistry, Genetics and Molecular Biology 9 8%
Chemistry 7 6%
Pharmacology, Toxicology and Pharmaceutical Science 7 6%
Other 18 16%
Unknown 18 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2021.
All research outputs
#5,085,382
of 16,956,273 outputs
Outputs from Drug Design, Development and Therapy
#299
of 1,668 outputs
Outputs of similar age
#56,452
of 192,532 outputs
Outputs of similar age from Drug Design, Development and Therapy
#11
of 35 outputs
Altmetric has tracked 16,956,273 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,668 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,532 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.